140 related articles for article (PubMed ID: 30540162)
1. Multifunctional Vector for Delivery of Genome Editing Plasmid Targeting β-Catenin to Remodulate Cancer Cell Properties.
He XY; Liu BY; Peng Y; Zhuo RX; Cheng SX
ACS Appl Mater Interfaces; 2019 Jan; 11(1):226-237. PubMed ID: 30540162
[TBL] [Abstract][Full Text] [Related]
2. Peptide and Aptamer Decorated Delivery System for Targeting Delivery of Cas9/sgRNA Plasmid To Mediate Antitumor Genome Editing.
Liu BY; He XY; Xu C; Ren XH; Zhuo RX; Cheng SX
ACS Appl Mater Interfaces; 2019 Jul; 11(27):23870-23879. PubMed ID: 31257851
[TBL] [Abstract][Full Text] [Related]
3. Aptamer/Peptide-Functionalized Genome-Editing System for Effective Immune Restoration through Reversal of PD-L1-Mediated Cancer Immunosuppression.
He XY; Ren XH; Peng Y; Zhang JP; Ai SL; Liu BY; Xu C; Cheng SX
Adv Mater; 2020 Apr; 32(17):e2000208. PubMed ID: 32147886
[TBL] [Abstract][Full Text] [Related]
4. Tumor targeted genome editing mediated by a multi-functional gene vector for regulating cell behaviors.
Liu BY; He XY; Zhuo RX; Cheng SX
J Control Release; 2018 Dec; 291():90-98. PubMed ID: 30339905
[TBL] [Abstract][Full Text] [Related]
5. A multifunctional non-viral vector for the delivery of MTH1-targeted CRISPR/Cas9 system for non-small cell lung cancer therapy.
Wang Y; Tang Y; Zhao XM; Huang G; Gong JH; Yang SD; Li H; Wan WJ; Jia CH; Chen G; Zhang XN
Acta Biomater; 2022 Nov; 153():481-493. PubMed ID: 36162766
[TBL] [Abstract][Full Text] [Related]
6. A Dual-Targeting Delivery System for Effective Genome Editing and In Situ Detecting Related Protein Expression in Edited Cells.
Liu BY; He XY; Xu C; Xu L; Ai SL; Cheng SX; Zhuo RX
Biomacromolecules; 2018 Jul; 19(7):2957-2968. PubMed ID: 29617556
[TBL] [Abstract][Full Text] [Related]
7. Cationic Polymer-Mediated CRISPR/Cas9 Plasmid Delivery for Genome Editing.
Zhang Z; Wan T; Chen Y; Chen Y; Sun H; Cao T; Songyang Z; Tang G; Wu C; Ping Y; Xu FJ; Huang J
Macromol Rapid Commun; 2019 Mar; 40(5):e1800068. PubMed ID: 29708298
[TBL] [Abstract][Full Text] [Related]
8. Reversal of tumor malignization and modulation of cell behaviors through genome editing mediated by a multi-functional nanovector.
Liu BY; He XY; Zhuo RX; Cheng SX
Nanoscale; 2018 Dec; 10(45):21209-21218. PubMed ID: 30417194
[TBL] [Abstract][Full Text] [Related]
9. Fluorinated Acid-Labile Branched Hydroxyl-Rich Nanosystems for Flexible and Robust Delivery of Plasmids.
Qi Y; Song H; Xiao H; Cheng G; Yu B; Xu FJ
Small; 2018 Oct; 14(42):e1803061. PubMed ID: 30238691
[TBL] [Abstract][Full Text] [Related]
10. In Vivo Delivery of CRISPR/Cas9 for Therapeutic Gene Editing: Progress and Challenges.
Mout R; Ray M; Lee YW; Scaletti F; Rotello VM
Bioconjug Chem; 2017 Apr; 28(4):880-884. PubMed ID: 28263568
[TBL] [Abstract][Full Text] [Related]
11. Artificial Virus Delivers CRISPR-Cas9 System for Genome Editing of Cells in Mice.
Li L; Song L; Liu X; Yang X; Li X; He T; Wang N; Yang S; Yu C; Yin T; Wen Y; He Z; Wei X; Su W; Wu Q; Yao S; Gong C; Wei Y
ACS Nano; 2017 Jan; 11(1):95-111. PubMed ID: 28114767
[TBL] [Abstract][Full Text] [Related]
12. CRISPR-Cas9-mediated genome editing in apple and grapevine.
Osakabe Y; Liang Z; Ren C; Nishitani C; Osakabe K; Wada M; Komori S; Malnoy M; Velasco R; Poli M; Jung MH; Koo OJ; Viola R; Nagamangala Kanchiswamy C
Nat Protoc; 2018 Dec; 13(12):2844-2863. PubMed ID: 30390050
[TBL] [Abstract][Full Text] [Related]
13. Nonviral gene editing via CRISPR/Cas9 delivery by membrane-disruptive and endosomolytic helical polypeptide.
Wang HX; Song Z; Lao YH; Xu X; Gong J; Cheng D; Chakraborty S; Park JS; Li M; Huang D; Yin L; Cheng J; Leong KW
Proc Natl Acad Sci U S A; 2018 May; 115(19):4903-4908. PubMed ID: 29686087
[TBL] [Abstract][Full Text] [Related]
14. Functionalized PDA/DEX-PEI@HA nanoparticles combined with sleeping-beauty transposons for multistage targeted delivery of CRISPR/Cas9 gene.
Ma K; Li W; Zhu G; Sun S; Chi H; Yin Y; Diao H; Xing XJ; Guo Z; Wang L; Xu W; Cui C; Xu J
Biomed Pharmacother; 2021 Oct; 142():112061. PubMed ID: 34449313
[TBL] [Abstract][Full Text] [Related]
15. Gene editing in clinical isolates of Candida parapsilosis using CRISPR/Cas9.
Lombardi L; Turner SA; Zhao F; Butler G
Sci Rep; 2017 Aug; 7(1):8051. PubMed ID: 28808289
[TBL] [Abstract][Full Text] [Related]
16. Self-Assembled Plasmid Delivery System for PPM1D Knockout to Reverse Tumor Malignancy.
Ren XH; He XY; Liu BY; Xu C; Cheng SX
ACS Appl Bio Mater; 2020 Nov; 3(11):7831-7839. PubMed ID: 35019523
[TBL] [Abstract][Full Text] [Related]
17. Genome editing of mutant KRAS through supramolecular polymer-mediated delivery of Cas9 ribonucleoprotein for colorectal cancer therapy.
Wan T; Chen Y; Pan Q; Xu X; Kang Y; Gao X; Huang F; Wu C; Ping Y
J Control Release; 2020 Jun; 322():236-247. PubMed ID: 32169537
[TBL] [Abstract][Full Text] [Related]
18. Methods for In Vivo CRISPR/Cas Editing of the Adult Murine Retina.
Hung SS; Li F; Wang JH; King AE; Bui BV; Liu GS; Hewitt AW
Methods Mol Biol; 2018; 1715():113-133. PubMed ID: 29188510
[TBL] [Abstract][Full Text] [Related]
19. CRISPR/Cas9 delivery with one single adenoviral vector devoid of all viral genes.
Ehrke-Schulz E; Schiwon M; Leitner T; Dávid S; Bergmann T; Liu J; Ehrhardt A
Sci Rep; 2017 Dec; 7(1):17113. PubMed ID: 29215041
[TBL] [Abstract][Full Text] [Related]
20. Retroviral Vectors for Cancer Gene Therapy.
Schambach A; Morgan M
Recent Results Cancer Res; 2016; 209():17-35. PubMed ID: 28101685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
